A 2026 factual update on the talcum powder litigation for ovarian cancer and mesothelioma. Learn who may qualify, how the MDL and bankruptcy-trust structures work, the evidence you need, state statutes of limitations, how claims are tiered, and the steps to start a claim.
A practical 2026 guide to how commercial truck and 18-wheeler accident settlements are actually valued in the US: medical bills, lost wages, and pain and suffering, the liable parties from driver to carrier to broker to manufacturer, FMCSA hours-of-service rules and ELD black-box evidence, the case timeline, attorney contingency fees, and the common mistakes that shrink recoveries.
Cohu (COHU) 2026 stock outlook. A deep, qualitative look at the semiconductor back-end test business, the installed-base-plus-consumables model built on contactors, heavy automotive and industrial chip exposure, recovery leverage off the test capex trough, and how Cohu stacks up against Teradyne and Advantest.
OPCH (Option Care Health) 2026 stock outlook. A qualitative deep dive into the largest independent home and alternate-site infusion provider: its national pharmacy-and-nursing scale moat, the site-of-care cost-savings engine, payer-mix and drug-pricing risk, reimbursement cuts, and how U.S. investors should frame the position.
LAMR (Lamar Advertising) 2026 stock outlook. A qualitative deep dive into the billboard REIT's permitting and location moat, its local-advertising cash cow, the economics of digital conversion, a peer comparison with OUTFRONT and Clear Channel, and the interest-rate, leverage, and cyclical-ad-demand risks that define the name.
PJT Partners (PJT) 2026 stock outlook. A qualitative deep dive into the pure advisory boutique model, counter-cyclical restructuring revenue, Park Hill fund placement, the M&A recovery leverage, peer comparison with Moelis, Evercore and Lazard, plus key-person and deal-cycle risk.
Mueller Water Products (MWA) 2026 stock outlook. Spec-in and installed-base moat in gate valves, fire hydrants and smart metering, IIJA and municipal capital spending tailwinds, housing-starts sensitivity, peer comparison, and a US-investor playbook.
BL (BlackLine) 2026 stock outlook. A qualitative deep dive into the accounting-close automation SaaS switching-cost moat, the SAP reseller partnership and S/4HANA migration cycle, decelerating growth, activist pressure, the pivot from growth to margin (Rule of 40), and the NRR and free-cash-flow metrics that actually matter.
EPR Properties (EPR) 2026 stock outlook. A deep, qualitative look at the monthly-dividend experiential net-lease REIT: theatre tenant concentration in AMC and Regal, non-theatre diversification into golf, waterparks and ski, rent coverage, interest-rate sensitivity, and dividend safety for US investors.
NUS (Nu Skin Enterprises) stock outlook for 2026. A qualitative deep dive into the structural decline of its beauty and wellness direct-selling model, device-driven recurring revenue from Rhyz, China regulatory risk, and whether its long dividend history is actually safe for income investors.
Photronics (PLAB) 2026 stock outlook. A deep qualitative look at the largest independent photomask vendor's oligopoly moat, design-start-driven revenue, fixed-cost operating leverage, China local-foundry demand, geopolitics, and exposure to the upstream semiconductor capex cycle.
Jack in the Box (JACK) stock outlook for 2026: how the franchise royalty model and refranchising strategy stack up against a highly levered securitized balance sheet, activist pressure, Del Taco integration and divestiture risk, and peer QSR competition for U.S. investors.
OPENEDGES Technology (394280) 2026 stock outlook. A qualitative deep dive into its on-chip memory controller, NPU and interconnect semiconductor IP licensing-plus-royalty model, comparison with ARM and Rambus, on-device AI demand leverage, and the unresolved path to sustained profitability.
PSK Holdings (031980) 2026 stock outlook. A Korean holding company whose value rests on its controlling stake in PSK Inc (319660), the dry-strip and photoresist-removal front-end equipment maker, leveraged to the memory capex cycle and HBM etch demand but weighed down by a persistent parent-subsidiary holding discount, analyzed qualitatively for US investors.
JW Holdings (096760) 2026 stock outlook. A deep qualitative look at Korea's IV-fluid oligopoly moat, JW Life Science and JW Bioscience subsidiary leverage, the gout and oncology pipeline, holding-company NAV discount, and drug-pricing risk for the JW Pharmaceutical group.
KBI Metal (024120) stock outlook for 2026. A close look at its wire, magnet-wire (winding), and auto-parts businesses, why the copper conversion spread matters more than the copper price, its leverage to grid and EV-motor demand, and what would trigger a re-rating of this low-PBR Korean materials stock.
Daemyung Energy (389260) 2026 stock outlook. A qualitative deep dive into its wind and solar EPC track record, recurring O&M revenue, owned generation-asset cash flow, RPS and REC policy sensitivity, interest-rate exposure, and project-pipeline execution risk for the KOSDAQ developer.
Chong Kun Dang Holdings (KRX: 001630) 2026 stock outlook. A qualitative deep dive into the pharmaceutical holding-company NAV discount, the earnings leverage from subsidiaries Chong Kun Dang, Kyongbo Pharm, CKD Bio and CKD Health, how the holdco differs from operating company Chong Kun Dang (185750), plus dividend appeal and owner-governance risk.
Interflex (051370) 2026 stock outlook. A qualitative deep dive into its flexible printed circuit board (FPCB) supply to Samsung Display OLED and Samsung Electronics smartphones, single-customer concentration risk, Chinese low-cost competition, OLED and automotive expansion leverage, plus US-investor tax and FX considerations.
KH Vatec (060720) 2026 stock outlook. A deep qualitative look at its foldable-smartphone hinge and metal-case franchise, the precision-machining moat, single-customer concentration on Samsung, set-launch seasonality, foldable penetration leverage, and the competing hinge-vendor landscape.
Suheung (008490) 2026 stock outlook. A deep qualitative look at its near-monopoly in domestic hard capsules and top-three global position, the health-supplement contract-manufacturing (ODM) growth lever, and the gelatin, currency, and demand-cycle risks facing this KOSDAQ materials name.
A qualitative 2026 outlook on JNTC (KOSDAQ 204270), the Korean maker of 3D tempered cover glass and connectors: its glass-forming moat, deep Samsung supply-chain exposure, the automotive-connector expansion, and sensitivity to smartphone demand, the won-dollar rate, and set-maker cycles.
A practical 2026 guide to cost segregation studies for US real estate investors. Learn how reclassifying building components into 5, 7, and 15-year assets accelerates depreciation, what studies typically cost, expected ROI ranges, how bonus depreciation fits in, and the recapture risk waiting at sale.
A practical 2026 breakdown of reverse mortgage (HECM) pros and cons: how payouts work, upfront and ongoing costs including MIP, inheritance and residency risks, and how HELOCs or downsizing stack up as alternatives for retirees.